{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T12:56:40Z","timestamp":1775825800896,"version":"3.50.1"},"reference-count":146,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2022,4,22]],"date-time":"2022-04-22T00:00:00Z","timestamp":1650585600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Pfizer Romania","award":["5468\/05.11.2021"],"award-info":[{"award-number":["5468\/05.11.2021"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Transthyretin amyloid cardiomyopathy (ATTR-CM) is an infiltrative disorder characterized by extracellular myocardial deposits of amyloid fibrils, with poor outcome, leading to heart failure and death, with significant treatment expenditure. In the era of a novel therapeutic arsenal of disease-modifying agents that target a myriad of pathophysiological mechanisms, timely and accurate diagnosis of ATTR-CM is crucial. Recent advances in therapeutic strategies shown to be most beneficial in the early stages of the disease have determined a paradigm shift in the screening, diagnostic algorithm, and risk classification of patients with ATTR-CM. The aim of this review is to explore the utility of novel specific non-invasive imaging parameters and biomarkers from screening to diagnosis, prognosis, risk stratification, and monitoring of the response to therapy. We will summarize the knowledge of the most recent advances in diagnostic, prognostic, and treatment tailoring parameters for early recognition, prediction of outcome, and better selection of therapeutic candidates in ATTR-CM. Moreover, we will provide input from different potential pathways involved in the pathophysiology of ATTR-CM, on top of the amyloid deposition, such as inflammation, endothelial dysfunction, reduced nitric oxide bioavailability, oxidative stress, and myocardial fibrosis, and their diagnostic, prognostic, and therapeutic implications.<\/jats:p>","DOI":"10.3390\/jcm11092360","type":"journal-article","created":{"date-parts":[[2022,4,23]],"date-time":"2022-04-23T08:14:06Z","timestamp":1650701646000},"page":"2360","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["New Advanced Imaging Parameters and Biomarkers\u2014A Step Forward in the Diagnosis and Prognosis of TTR Cardiomyopathy"],"prefix":"10.3390","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5489-4052","authenticated-orcid":false,"given":"Roxana Cristina","family":"Rimbas","sequence":"first","affiliation":[{"name":"Cardiology and Cardiovascular Surgery Department, University and Emergency Hospital, 050098 Bucharest, Romania"},{"name":"Cardiology Department, University of Medicine and Pharmacy Carol Davila, 020021 Bucharest, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anca","family":"Balinisteanu","sequence":"additional","affiliation":[{"name":"Cardiology and Cardiovascular Surgery Department, University and Emergency Hospital, 050098 Bucharest, Romania"},{"name":"Cardiology Department, University of Medicine and Pharmacy Carol Davila, 020021 Bucharest, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefania Lucia","family":"Magda","sequence":"additional","affiliation":[{"name":"Cardiology and Cardiovascular Surgery Department, University and Emergency Hospital, 050098 Bucharest, Romania"},{"name":"Cardiology Department, University of Medicine and Pharmacy Carol Davila, 020021 Bucharest, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simona Ionela","family":"Visoiu","sequence":"additional","affiliation":[{"name":"Cardiology Department, University of Medicine and Pharmacy Carol Davila, 020021 Bucharest, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea Olivia","family":"Ciobanu","sequence":"additional","affiliation":[{"name":"Cardiology and Cardiovascular Surgery Department, University and Emergency Hospital, 050098 Bucharest, Romania"},{"name":"Cardiology Department, University of Medicine and Pharmacy Carol Davila, 020021 Bucharest, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elena","family":"Beganu","sequence":"additional","affiliation":[{"name":"Cardiology and Cardiovascular Surgery Department, University and Emergency Hospital, 050098 Bucharest, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alina Ioana","family":"Nicula","sequence":"additional","affiliation":[{"name":"Cardiology Department, University of Medicine and Pharmacy Carol Davila, 020021 Bucharest, Romania"},{"name":"Radiology Department, University and Emergency Hospital, 050098 Bucharest, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dragos","family":"Vinereanu","sequence":"additional","affiliation":[{"name":"Cardiology and Cardiovascular Surgery Department, University and Emergency Hospital, 050098 Bucharest, Romania"},{"name":"Cardiology Department, University of Medicine and Pharmacy Carol Davila, 020021 Bucharest, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2022,4,22]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"965","DOI":"10.2967\/jnumed.120.245381","article-title":"Molecular Imaging of Cardiac Amyloidosis","volume":"61","author":"Ahmad","year":"2020","journal-title":"J. Nucl. Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.jacc.2020.11.006","article-title":"Prevalence and Outcomes of Concomitant Aortic Stenosis and Cardiac Amyloidosis","volume":"77","author":"Nitsche","year":"2021","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"e7","DOI":"10.1161\/CIR.0000000000000792","article-title":"Cardiac Amyloidosis: Evolving Diagnosis and Management. A Scientific Statement Fron the American Heart Association","volume":"142","author":"Kittleson","year":"2020","journal-title":"Circulation"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"2641","DOI":"10.1016\/S0140-6736(15)01274-X","article-title":"Systemic amyloidosis","volume":"387","author":"Wechalekar","year":"2016","journal-title":"Lancet"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1161\/CIRCULATIONAHA.111.078915","article-title":"Transthyretin (TTR) cardiac amyloidosis","volume":"126","author":"Ruberg","year":"2012","journal-title":"Circulation"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"2585","DOI":"10.1093\/eurheartj\/ehv338","article-title":"Wild-type transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction","volume":"36","author":"Robles","year":"2015","journal-title":"Eur. Heart J."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1016\/j.cjca.2019.12.034","article-title":"Canadian Cardiovascular Society\/Canadian Heart Failure Society joint position statement on the evaluation and management of patients with cardiac amyloidosis","volume":"36","author":"Fine","year":"2020","journal-title":"Can. J. Cardiol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"590057","DOI":"10.3389\/fcvm.2020.590557","article-title":"The role of multimodality imaging in the diagnosis of cardiac amylodosis. A focused update","volume":"7","author":"Khanna","year":"2020","journal-title":"Front. Cardiovasc. Med."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1002\/ejhf.2140","article-title":"Diagnosis and treatment of cardiac amyloidosis. A position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases","volume":"23","author":"Rapezzi","year":"2021","journal-title":"Eur. J. Heart Fail."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.echo.2017.08.017","article-title":"Prognostic and added value of two-dimensional global longitudinal strain for prediction of survival in patients with light chain amyloidosis undergoing autologous hematopoietic cell transplantation","volume":"31","author":"Pun","year":"2018","journal-title":"J. Am. Soc. Echocardiogr."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"e006075","DOI":"10.1161\/CIRCHEARTFAILURE.119.006075","article-title":"Expert consensus recommendations for the suspicion and diagnosis of transthyretin cardiac amyloidosis","volume":"12","author":"Maurer","year":"2019","journal-title":"Circ. Heart Fail."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1001\/jamacardio.2016.5864","article-title":"Identification of transthyretin cardiac amyloidosis using serum retinol-binding protein 4 and a clinical prediction model","volume":"2","author":"Arvanitis","year":"2017","journal-title":"JAMA Cardiol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1007\/s10741-014-9462-7","article-title":"Natural history and therapy of TTR-cardiac amyloidosis: Emerging disease-modifying therapies from organ transplantation to stabilizer and silencer drugs","volume":"20","author":"Drachman","year":"2015","journal-title":"Heart Fail. Rev."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1111\/joim.12383","article-title":"Cardiac amyloidosis: Where are we today?","volume":"278","author":"Patel","year":"2015","journal-title":"J. Intern. Med."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"2879","DOI":"10.1093\/eurheartj\/ehx350","article-title":"Unveiling transthyretin cardiac amyloidoisis and its predictors among elderly patients with severe aortic stenosis undergoing transcatheter aortic valve replacement","volume":"38","author":"Castano","year":"2017","journal-title":"Eur. Heart J."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"2759","DOI":"10.1093\/eurheartj\/ehaa170","article-title":"Prevalence and outcome of dual aortic stenosis and cardiac amyloid pathology in patients referred for transcatheter aortic valve implantation","volume":"41","author":"Scully","year":"2020","journal-title":"Eur. Heart J."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"e005066","DOI":"10.1161\/CIRCIMAGING.116.005066","article-title":"Occult Transthyretin Cardiac Amyloid in Severe Calcific Aortic Stenosis: Prevalence and prognosis in patients undergoing surgical aortic valve replacement","volume":"9","author":"Treibel","year":"2016","journal-title":"Circ. Cardiovasc. Imaging"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1080\/07853890701842988","article-title":"Senile systemic amyloidosis affects 25% of the very aged and associates with genetic variation in alpha2-macroglobulin and tau: A population-based autopsy study","volume":"40","author":"Tanskanen","year":"2008","journal-title":"Ann. Med."},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Li, W., Uppal, D., Wang, Y.C., Xu, X., Kokkinidis, D.G., Travin, M.I., and Tauras, J.M. (2021). Nuclear Imaging for the Diagnosis of Cardiac Amyloidosis in 2021. Diagnostics, 11.","DOI":"10.3390\/diagnostics11060996"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/j.jchf.2019.04.010","article-title":"Screening for Transthyretin Amyloid Cardiomyopathy in Everyday Practice","volume":"7","author":"Witteles","year":"2019","journal-title":"JACC Heart Fail."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.jacc.2020.11.007","article-title":"Concomitant Cardiac Amyloidosis in Severe Aortic Stenosis. The Trojan Horse?","volume":"77","author":"Pibarot","year":"2021","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"2109","DOI":"10.1007\/s00415-019-09688-0","article-title":"Expert consensus recommendations to improve diagnosis of ATTR amyloidosis with polyneuropathy","volume":"268","author":"Adams","year":"2020","journal-title":"J. Neurol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.jacc.2016.05.009","article-title":"Amyloid cardiomyopathy","volume":"68","author":"Benson","year":"2016","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1002\/ajh.25149","article-title":"Immunoglobulin light chain amyloidosis: 2018 update on diagnosis, prognosis, and treatment","volume":"93","author":"Gertz","year":"2018","journal-title":"Am. J. Hematol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1001\/jama.2020.5493","article-title":"Systemic amyloidosis recognition, prognosis, and therapy A systematic review","volume":"324","author":"Gertz","year":"2020","journal-title":"JAMA"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1038\/s41572-018-0034-3","article-title":"Systemic immunoglobulin light chain amyloidosis","volume":"4","author":"Merlini","year":"2018","journal-title":"Nat. Rev. Dis. Primers"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"e000881","DOI":"10.1136\/openhrt-2018-000881","article-title":"Role of cardiovascular imaging for the diagnosis and prognosis of cardiac amyloidosis","volume":"5","author":"Agha","year":"2018","journal-title":"Open Heart"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1001\/archinte.165.12.1425","article-title":"Senile systemic amyloidosis presenting with heart failure","volume":"165","author":"Ng","year":"2005","journal-title":"Arch. Intern. Med."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1038\/nrcardio.2013.129-c1","article-title":"Troponins in cardiac amyloidosis: Multipurpose markers","volume":"11","author":"Perfetto","year":"2014","journal-title":"Nat. Rev. Cardiol."},{"key":"ref_30","first-page":"1287","article-title":"Obstructive intramural coronary amyloidosis and myocardial ischemia are common in primary amyloidosis","volume":"118","author":"Wittich","year":"2005","journal-title":"Am. J. Med."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/j.jchf.2014.03.009","article-title":"Coronary microvascular dysfunction is related to abnormalities in myocardial structure and function in cardiac amyloidosis","volume":"2","author":"Dorbala","year":"2014","journal-title":"JACC Heart Fail."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1007\/s11897-019-00446-x","article-title":"Amyloidosis in Heart Failure","volume":"16","author":"Ihne","year":"2019","journal-title":"Curr. Heart Fail. Rep."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"2872","DOI":"10.1016\/j.jacc.2019.04.003","article-title":"Transthyretin amyloid cardiomyopathy: JACC state-of-the-art review","volume":"73","author":"Ruberg","year":"2019","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1136\/hrt.2009.190405","article-title":"Amyloid diseases of the heart: Assessment, diagnosis, and referral","volume":"97","author":"Dubrey","year":"2011","journal-title":"Heart"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"58","DOI":"10.3109\/13506129.2015.1135792","article-title":"Carpal tunnel syndrome: A common initial symptom of systemic wild-type ATTR (ATTRwt) amyloidosis","volume":"23","author":"Nakagawa","year":"2016","journal-title":"Amyloid"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"223","DOI":"10.3109\/03009734.2014.895786","article-title":"Transthyretin derived amyloidosis: Probably a common cause of lumbar spinal stenosis","volume":"119","author":"Westermark","year":"2014","journal-title":"Ups. J. Med. Sci."},{"key":"ref_37","first-page":"284","article-title":"Cardiac amyloidosis an underdiagnosed cause of heart failure with preserved ejection fraction\u2014updated diagnosis and treatment options","volume":"31","author":"Rimbas","year":"2021","journal-title":"Rom. J. Cardiol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1161\/CIRCULATIONAHA.109.924167","article-title":"Comparative evaluation of left and right ventricular endomyocardial biopsy: Differences in complication rate and diagnostic performance","volume":"122","author":"Yilmaz","year":"2010","journal-title":"Circulation"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.4065\/mcp.2011.0296","article-title":"Current Status of Endomyocardial Biopsy","volume":"86","author":"From","year":"2011","journal-title":"Mayo Clin. Proc."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1093\/eurheartj\/ehv583","article-title":"Prevalence and clinical phenotype of hereditary transthyretin amyloid cardiomyopathy in patients with increased left ventricular thickness","volume":"37","author":"Damy","year":"2016","journal-title":"Eur. Heart J."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1016\/j.amjcard.2014.07.026","article-title":"Prevalence and prognostic significance of low QRS voltage among the three main types of cardiac amyloidosis","volume":"114","author":"Cyrille","year":"2014","journal-title":"Am. J. Cardiol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"e000289","DOI":"10.1136\/openhrt-2015-000289","article-title":"Clinical, ECG and echocardiographic clues to the diagnosis of TTR-related cardiomyopathy","volume":"3","author":"Damy","year":"2016","journal-title":"Open Heart"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/s13023-020-1309-9","article-title":"Clinical characteristics in patients with hereditary amyloidosis with Glu54Gln transthyretin identified in the Romanian population","volume":"15","author":"Jercan","year":"2020","journal-title":"Orphanet J. Rare Dis."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.ahj.2012.04.013","article-title":"The electrocardiographic features associated with cardiac amyloidosis of variant transthyretin isoleucine 122 type in afro-caribbean patients","volume":"164","author":"Dungu","year":"2012","journal-title":"Am. Heart J."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.amjcard.2004.10.028","article-title":"Electrocardiographic findings in primary systemic amyloidosis and biopsy-proven cardiac involvement","volume":"95","author":"Murtagh","year":"2005","journal-title":"Am. J. Cardiol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1111\/anec.12036","article-title":"Diagnostic and prognostic value of low QRS voltages in cardiac AL amyloidosis","volume":"18","author":"Mussinelli","year":"2013","journal-title":"Ann. Noninvasive Electrocardiol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/j.jacc.2003.08.043","article-title":"Noninvasive diagnosis of biopsy-proven cardiac amyloidosis","volume":"43","author":"Rahman","year":"2004","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"27","DOI":"10.3109\/13506129.2012.761967","article-title":"Evaluation of patients with cardiac amyloidosis using echocardiography, ECG and right heart catheterization","volume":"20","author":"Granstam","year":"2013","journal-title":"Amyloid"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1111\/anec.12032","article-title":"Prevalence and prognostic value of conduction disturbances at the time of diagnosis of cardiac al amyloidosis","volume":"18","author":"Boldrini","year":"2013","journal-title":"Ann. Noninvasive Electrocardiol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"2156","DOI":"10.1016\/j.ijcard.2012.05.097","article-title":"Prognostic value of fragmented QRS in cardiac AL amyloidosis","volume":"167","author":"Perlini","year":"2013","journal-title":"Int. J. Cardiol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/j.amjcard.2011.09.052","article-title":"Value of electrocardiogram in the differentiation of hypertensive heart disease, hypertrophic cardiomyopathy, aortic stenosis, amyloidosis, and Fabry disease","volume":"109","author":"Namdar","year":"2012","journal-title":"Am. J. Cardiol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/j.ejheart.2007.01.012","article-title":"Non-invasive predictors of survival in cardiac amyloidosis","volume":"9","author":"Kristen","year":"2007","journal-title":"Eur. J. Heart Fail."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"7746","DOI":"10.1038\/s41598-019-44245-9","article-title":"Associations of electrocardiographic parameters with left vetricular longitudinal strain and prognosis in cardiac light chain amyloidosis","volume":"9","author":"Kim","year":"2019","journal-title":"Sci. Rep."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1007\/s10554-020-02059-1","article-title":"Indexed left ventricular mass to QRS voltage ratio is associated with heart failure hospitalizations in patients with cardiac amyloidosis","volume":"37","author":"Slivnick","year":"2021","journal-title":"Int. J. Cardiovasc. Imaging"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1016\/j.jcmg.2019.10.011","article-title":"Multiparametric Echocardiography Scores for the Diagnosis of Cardiac Amyloidosis","volume":"13","author":"Boldrini","year":"2020","journal-title":"JACC Cardiovasc. Imaging"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1002\/ehf2.12518","article-title":"Transthyretin cardiac amyloidosis: An update on diagnosis and treatment","volume":"6","author":"Yamamoto","year":"2019","journal-title":"ESC Heart Fail"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1007\/s11886-019-1180-2","article-title":"Cardiac Amyloidosis: Updates in Imaging","volume":"21","author":"Chacko","year":"2019","journal-title":"Curr. Cardiol. Rep."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1007\/s11886-018-1065-9","article-title":"Echocardiography in Sarcoidosis","volume":"20","author":"Kurmann","year":"2018","journal-title":"Curr. Cardiol. Rep."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1007\/s12574-015-0249-1","article-title":"The role of echocardiography in the non-invasive diagnosis of cardiac amyloidosis","volume":"13","author":"Cacciapuoti","year":"2015","journal-title":"J. Echocardiogr."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1007\/s11886-019-1094-z","article-title":"Echocardiographic Findings in Cardiac Amyloidosis: Inside Two-Dimensional, Doppler, and Strain Imaging","volume":"21","author":"Recupero","year":"2019","journal-title":"Curr. Cardiol. Rep."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1136\/hrt.78.1.74","article-title":"Familial and primary (AL) cardiac amyloidosis: Echocardiographically similar diseases with distinctly different clinical outcomes","volume":"78","author":"Dubrey","year":"1997","journal-title":"Heart"},{"key":"ref_62","doi-asserted-by":"crossref","unstructured":"Sasc\u0103u, R., Anghel, L., Clement, A., Bostan, M., Radu, R., and St\u0103tescu, C. (2021). The Importance of Multimodality Imaging in the Diagnosis and Management of Patients with Infiltrative Cardiomyopathies: An Update. Diagnostics, 11.","DOI":"10.3390\/diagnostics11020256"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1093\/ehjci\/jeaa063","article-title":"Multimodality imaging in cardiac amyloidosis: A primer for cardiologists","volume":"21","author":"Jurcut","year":"2020","journal-title":"Eur. Heart J. Cardiovasc Imaging"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1007\/s10741-014-9466-3","article-title":"Echocardiography in cardiac amyloidosis","volume":"20","author":"Falk","year":"2015","journal-title":"Heart Fail. Rev."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1016\/j.hlc.2019.04.017","article-title":"Echocardiography in Infiltrative Cardiomyopathy","volume":"28","author":"Perry","year":"2019","journal-title":"Heart Lung Circ."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1016\/j.echo.2007.02.025","article-title":"Detection of left ventricular systolic dysfunction in cardiac amyloidosis with strain rate echocardiography","volume":"20","author":"Bellavia","year":"2007","journal-title":"J. Am. Soc. Echocardiogr."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"e005588","DOI":"10.1161\/CIRCIMAGING.116.005588","article-title":"Echo parameters for differential diagnosis in cardiac amyloidosis: A head-to-head comparison of deformation and nondeformation parameters","volume":"10","author":"Pagourelias","year":"2017","journal-title":"Circ. Cardiovasc. Imaging"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1136\/heartjnl-2012-302353","article-title":"Relative apical sparing of longitudinal strain using two-dimensional speckle-tracking echocardiography is both sensitive and specific for the diagnosis of cardiac amyloidosis","volume":"98","author":"Phelan","year":"2012","journal-title":"Heart"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1161\/CIRCIMAGING.113.000683","article-title":"Effect of combined systolic and diastolic functional parameter assessment for differentiation of cardiac amyloidosis from other causes of concentric left ventricular hypertrophy","volume":"6","author":"Liu","year":"2013","journal-title":"Circ. Cardiovasc. Imaging"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1253\/circj.CJ-14-1328","article-title":"Visual assessment of relative apical sparing pattern is more useful than quantitative assessment for diagnosing cardiac amyloidosis in borderline or mildly increased LV thickness","volume":"79","author":"Lee","year":"2015","journal-title":"Circ. J."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1080\/13506129.2018.1493989","article-title":"Right ventricular involvement in transthyretin amyloidosis","volume":"25","author":"Arvidsson","year":"2018","journal-title":"Amyloid"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/j.cjca.2020.01.020","article-title":"Determinants and prognostic significance of serial right heart function changes in patients with cardiac amyloidosis","volume":"36","author":"Fine","year":"2020","journal-title":"Can. J. Cardiol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1093\/eurheartj\/ehz905","article-title":"Echocardiographic phenotype and prognosis in transthyretin cardiac amyloidosis","volume":"41","author":"Chacko","year":"2020","journal-title":"Eur. Heart J."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1016\/j.jcmg.2018.02.016","article-title":"Cardiac sructural and functional consequences of amyloid deposition by cardiac magnetic resonance and echocardiography and their prognostic roles","volume":"12","author":"Knight","year":"2019","journal-title":"JACC Cardiovasc. Imaging"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"e001346","DOI":"10.1136\/openhrt-2020-001346","article-title":"Can myocardial work indices contribute to the exploration of patients with cardiac amyloidosis?","volume":"7","author":"Cariou","year":"2020","journal-title":"Open Heart"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1007\/s10741-019-09796-z","article-title":"Speckle tracking echocardiography in cardiac amyloidosis","volume":"24","author":"Stricagnoli","year":"2019","journal-title":"Heart Fail. Rev."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/j.echo.2019.11.018","article-title":"Left ventricular pressure-strain-derived myocardial work at rest and during exercise in patients with cardiac amyloidosis","volume":"33","author":"Clemmensen","year":"2020","journal-title":"J. Am. Soc. Echocardiogr."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/13506129.2018.1430027","article-title":"Reduced left atrial myocardial deformation irrespective of cavity size: A potential cause for atrial arrhythmia in hereditary transthyretin amyloidosis","volume":"25","author":"Henein","year":"2018","journal-title":"Amyloid"},{"key":"ref_79","first-page":"1128","article-title":"Left atrial structure and function in cardiac amyloidosis","volume":"18","author":"Nochioka","year":"2017","journal-title":"Eur. Heart J. Cardiovasc. Imaging"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"1830","DOI":"10.1253\/circj.CJ-16-0364","article-title":"Left Atrial Morphology, Size and Function in Patients With Transthyretin Cardiac Amyloidosis and Primary Hypertrophic Cardiomyopathy-Comparative Strain Imaging Study","volume":"80","author":"Dattilo","year":"2016","journal-title":"Circ. J."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1111\/j.1540-8175.2012.01680.x","article-title":"Differentiating cardiac amyloidosis and hypertrophic cardiomyopathy by use of three-dimensional speckle tracking echocardiography","volume":"29","author":"Baccouche","year":"2012","journal-title":"Echocardiography"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","article-title":"2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) With the special contribution of the Heart Failure Association (HFA) of the ESC","volume":"42","author":"McDonagh","year":"2021","journal-title":"Eur. Heart J."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1161\/CIRCIMAGING.113.001396","article-title":"How to image cardiac amyloidosis","volume":"7","author":"Falk","year":"2014","journal-title":"Circ. Cardiovasc. Imaging"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"e450","DOI":"10.1161\/CIRCULATIONAHA.116.021162","article-title":"Response to letters regarding article, \u2018prognostic value of late gadolinium enhancement cardiovascular magnetic resonance in cardiac amyloidosis\u2019","volume":"133","author":"Fontana","year":"2016","journal-title":"Circulation"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1007\/s12471-017-1046-4","article-title":"Role of cardiovascular magnetic resonance in suspected cardiac amyloidosis: Late gadolinium enhancement pattern as mortality predictor","volume":"26","author":"Baroni","year":"2018","journal-title":"Neth. Heart J"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1016\/j.jcmg.2016.01.036","article-title":"Prognostic value of late gadolinium enhancement CMR in systemic amyloidosis","volume":"9","author":"Raina","year":"2016","journal-title":"JACC Cardiovasc. Imaging"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1007\/s10741-014-9470-7","article-title":"Cardiovascular magnetic resonance for amyloidosis","volume":"20","author":"Fontana","year":"2015","journal-title":"Heart Fail. Rev."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1016\/j.jcmg.2012.11.013","article-title":"Noncontrast T1 mapping for the diagnosis of cardiac amyloidosis","volume":"6","author":"Karamitsos","year":"2013","journal-title":"JACC Cardiovasc. Imaging"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.jcmg.2019.03.026","article-title":"Noncontrast Magnetic Resonance for the Diagnosis of Cardiac Amyloidosis","volume":"13","author":"Baggiano","year":"2020","journal-title":"JACC Cardiovasc. Imaging"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1136\/heartjnl-2012-302346","article-title":"Cardiovascular magnetic resonance measurement of myocardial extracellular volume in health and disease","volume":"98","author":"Sado","year":"2012","journal-title":"Heart"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1161\/CIRCIMAGING.112.000070","article-title":"Identification and assessment of Anderson-Fabry disease by cardiovascular magnetic resonance noncontrast myocardial T1 mapping","volume":"6","author":"Sado","year":"2013","journal-title":"Circ. Cardiovasc. Imaging"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"A1","DOI":"10.1136\/heartjnl-2017-311399.1","article-title":"Multiparametric Mapping to Understand Pathophysiology in Cardiac Amyloidosis","volume":"103","author":"Kotecha","year":"2017","journal-title":"Heart"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1186\/s12968-017-0389-8","article-title":"Clinical recommendations for cardiovascular magnetic resonance mapping of T1, T2, T2* and extracellular volume: A consensus statement by the Society for Cardiovascular Magnetic Resonance (SCMR) endorsed by the European Association for Cardiovascular Imaging (EACVI)","volume":"19","author":"Messroghli","year":"2017","journal-title":"J. Cardiovasc. Magn. Reson."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"599","DOI":"10.4330\/wjc.v12.i12.599","article-title":"Diagnostic and prognostic value of cardiac imaging in amyloidosis","volume":"12","year":"2020","journal-title":"World J. Cardiol."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1093\/ehjci\/jew325","article-title":"Prognostic utility of the Perugini grading of 99mTc-DPD scintigraphy in transthyretin (ATTR) amyloidosis and its relationship with skeletal muscle and soft tissue amyloid","volume":"18","author":"Hutt","year":"2017","journal-title":"Eur. Heart J Cardiovasc. Imaging"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.carpath.2016.07.001","article-title":"Varying levels of small microcalcifications and macrophages in ATTR and AL cardiac amyloidosis: Implications for utilizing nuclear medicine studies to subtype amyloidosis","volume":"25","author":"Stats","year":"2016","journal-title":"Cardiovasc. Pathol."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"2404","DOI":"10.1161\/CIRCULATIONAHA.116.021612","article-title":"Nonbiopsy Diagnosis of Cardiac Transthyretin Amyloidosis","volume":"133","author":"Gillmore","year":"2016","journal-title":"Circulation"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1016\/j.jacc.2005.05.073","article-title":"Noninvasive etiologic diagnosis of cardiac amyloidosis using 99mTc-3,3-diphosphono-1,2-propanodicarboxylic acid scintigraphy","volume":"46","author":"Perugini","year":"2005","journal-title":"J Am. Coll. Cardiol."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1007\/s00259-018-4013-4","article-title":"Diagnostic accuracy of bone scintigraphy in the assessment of cardiac transthyretin-related amyloidosis: A bivariate meta-analysis","volume":"45","author":"Treglia","year":"2018","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"e000098","DOI":"10.1161\/JAHA.113.000098","article-title":"Senile systemic amyloidosis: Clinical features at presentation and outcome","volume":"2","author":"Pinney","year":"2013","journal-title":"J. Am. Heart Assoc."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1007\/s12350-020-02328-5","article-title":"Comparison of planar with tomographic pyrophosphate scintigraphy for transthyretin cardiac amyloidosis: Perils and pitfalls","volume":"28","author":"Asif","year":"2021","journal-title":"J. Nucl. Cardiol."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1093\/ehjci\/jeu107","article-title":"Utility and limitations of 3,3-diphosphono-1,2-propanodicarboxylic acid scintigraphy in systemic amyloidosis","volume":"15","author":"Hutt","year":"2014","journal-title":"Eur. Heart J. Cardiovasc. Imaging"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"e010249","DOI":"10.1161\/CIRCIMAGING.119.010249","article-title":"Efficient 1-Hour Technetium-99 m Pyrophosphate Imaging Protocol for the Diagnosis of Transthyretin Cardiac Amyloidosis","volume":"13","author":"Masri","year":"2020","journal-title":"Circ. Cardiovasc. Imaging"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.ijcard.2020.02.030","article-title":"Diphosphonate single-photon emission computed tomography in cardiac transthyretin amyloidosis","volume":"307","author":"Grigoratos","year":"2020","journal-title":"Int. J. Cardiol."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.jcmg.2017.06.020","article-title":"Regional variation in technetium pyrophosphate uptake in transthyretin cardiac amyloidosis and impact on mortality","volume":"11","author":"Sperry","year":"2018","journal-title":"JACC Cardiovasc. Imaging"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"1822","DOI":"10.1007\/s00259-020-05144-8","article-title":"Cardiac transthyretin amyloidosis 99mTc-DPD SPECT correlates with strain echocardiography and biomarkers","volume":"48","author":"Axelsson","year":"2021","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1007\/s12350-018-1365-x","article-title":"Cardiac amyloidosis imaging with amyloid positron emission tomography: A systematic review and metaanalysis","volume":"27","author":"Kim","year":"2020","journal-title":"J. Nucl. Cardiol."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/B978-0-12-394816-8.00002-7","article-title":"Using Pittsburgh Compound B for in vivo PET imaging of fibrillar amyloid-beta","volume":"64","author":"Cohen","year":"2012","journal-title":"Adv. Pharmacol."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1080\/13506129.2020.1798223","article-title":"Non-invasive detection and differentiation of cardiac amyloidosis using 99mTc-pyrophosphate scintigraphy and 11C-Pittsburgh compound B PET imaging","volume":"27","author":"Takasone","year":"2020","journal-title":"Amyloid"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1007\/s13139-015-0338-0","article-title":"Imaging Findings and Literature Review of 18F-FDG PET\/CT in Primary Systemic AL Amyloidosis","volume":"49","author":"Lee","year":"2015","journal-title":"Nucl. Med. Mol. Imaging"},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1148\/rg.2020190069","article-title":"Trends in Diagnostic Imaging of Cardiac Amyloidosis: Emerging Knowledge and Concepts","volume":"40","author":"Oda","year":"2020","journal-title":"Radiographics"},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1016\/j.jcct.2015.07.001","article-title":"Extracellular volume quantification by dynamic equilibrium cardiac computed tomography in cardiac amyloidosis","volume":"9","author":"Treibel","year":"2015","journal-title":"J. Cardiovasc. Comput. Tomogr."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"2638","DOI":"10.1016\/j.jacc.2019.09.056","article-title":"Aortic Stenosis and Cardiac Amyloidosis: JACC Review Topic of the Week","volume":"74","author":"Ternacle","year":"2019","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1080\/13506129.2019.1597701","article-title":"Myocardial extracellular volume quantification using CT for the identification of occult cardiac amyloidosis in patients with severe aortic stenosis referred for transcatheter aortic valve replacement","volume":"26","author":"Oda","year":"2019","journal-title":"Amyloid"},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"170046","DOI":"10.1183\/16000617.0046-2017","article-title":"The lung in amyloidosis","volume":"26","author":"Milani","year":"2017","journal-title":"Eur. Respir. Rev."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"221","DOI":"10.2174\/1573403X15666190722154152","article-title":"Transthyretin Cardiac Amyloidosis and Aortic Stenosis: Connection and Therapeutic Implications","volume":"16","author":"Penalver","year":"2020","journal-title":"Curr. Cardiol. Rev."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1093\/eurheartj\/ehaa131","article-title":"Untangling the physiology of transthyretin cardiac amyloidosis by leveraging echocardiographically derived pressure\u2013volume indices","volume":"41","author":"Rosenblum","year":"2020","journal-title":"Eur. Heart J."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1056\/NEJMoa1805689","article-title":"ATTR-ACT Study Investigators. Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy","volume":"379","author":"Maurer","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1161\/CIRCULATIONAHA.118.035831","article-title":"Effects of patisiran, an RNA interference therapeutic, on cardiac parameters in patients with hereditary transthyretin-mediated amyloidosis","volume":"139","author":"Solomon","year":"2019","journal-title":"Circulation"},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1056\/NEJMoa1716793","article-title":"Inotersen treatment for patients with hereditary transthyretin amyloidosis","volume":"379","author":"Benson","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1016\/j.jchf.2020.03.007","article-title":"Utility of biomarkers in cardiac amyloidosis","volume":"8","author":"Abraham","year":"2020","journal-title":"JACC Heart Fail."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"e004000","DOI":"10.1161\/CIRCHEARTFAILURE.117.004000","article-title":"Use of serum transthyretin as a prognostic indicator and predictor of outcome in cardiac amyloid disease associated with wild-type transthyretin","volume":"11","author":"Hanson","year":"2018","journal-title":"Circ. Heart Fail."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/j.cjca.2019.12.020","article-title":"Biomarkers and prediction of prognosis in transthyretin-related cardiac amyloidosis; direct comparison of two staging systems","volume":"36","author":"Cappelli","year":"2020","journal-title":"Can. J. Cardiol."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1016\/j.jacc.2016.06.033","article-title":"Natural history of wild-type transthyretin cardiac amyloidosis and risk stratification using a novel staging system","volume":"68","author":"Grogan","year":"2016","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"2799","DOI":"10.1093\/eurheartj\/ehx589","article-title":"A new staging system for cardiac transthyretin amyloidosis","volume":"39","author":"Gillmore","year":"2018","journal-title":"Eur. Heart J."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1002\/ehf2.12203","article-title":"Diagnostic utility of cardiac troponin T level in patients with cardiac amyloidosis","volume":"5","author":"Takashio","year":"2017","journal-title":"ESC Heart Fail."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1007\/s11897-020-00457-z","article-title":"Disease-specific biomarkers in transthyretin cardiac amyloidosis","volume":"17","author":"Hendren","year":"2020","journal-title":"Curr. Heart Fail. Rep."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1716153","article-title":"Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis","volume":"379","author":"Adams","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"5","DOI":"10.3389\/fphys.2019.00005","article-title":"The extracellular protein, transthyretin is an oxidative stress biomarker","volume":"10","author":"Sharma","year":"2019","journal-title":"Front. Physiol."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1186\/s13023-015-0326-6","article-title":"Efficacy and safety of patisiran for familial amyloidotic polyneuropathy: A phase II multi-dose study","volume":"10","author":"Suhr","year":"2015","journal-title":"Orphanet J. Rare Dis."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1080\/13506129.2017.1295371","article-title":"Retino binding protein 4 (RBP4) concentration identifies V122I transthyretin cardiac amyloidosis","volume":"2","author":"Arvanitis","year":"2017","journal-title":"Amyloid"},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"e005868","DOI":"10.1161\/JAHA.112.005868","article-title":"Circulating matrix metalloproteinases and tissue inhibitors of metalloproteinases in cardiac amyloidosis","volume":"2","author":"Tanaka","year":"2013","journal-title":"J. Am. Heart Assoc."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1080\/13506129.2016.1242480","article-title":"Plasma hepatocyte growth factor is a novel marker of AL cardiac amyloidosis","volume":"23","author":"Swiger","year":"2016","journal-title":"Amyloid"},{"key":"ref_134","doi-asserted-by":"crossref","unstructured":"Azevedo, E.P., Guimaraes-Costa, A.B., Bandeira-Melo, C., Chimelli, L., Waddington-Cruz, M., Saraiva, E.M., Palhano, F.L., and Foguel, D. (2019). Inflammatory profiling of patients with familial amyloid polyneuropathy. BMC Neurol., 19.","DOI":"10.1186\/s12883-019-1369-4"},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1038\/nrcardio.2014.165","article-title":"Pathophysiology and treatment of cardiac amyloidosis","volume":"12","author":"Gertz","year":"2015","journal-title":"Nat. Rev. Cardiol."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.cca.2014.10.023","article-title":"Multiple biomarker strategies for risk stratification in heart failure","volume":"443","year":"2015","journal-title":"Clin. Chim. Acta"},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"e412","DOI":"10.1212\/WNL.0000000000011090","article-title":"Neurofilament light chain as a biomarker of hereditary transthyretin-mediated amyloidosis","volume":"96","author":"Ticau","year":"2021","journal-title":"Neurology"},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1038\/labinvest.2013.83","article-title":"Fibroblasts endocytose and degrade tranthyretin aggregates in transthyretin-related amyloidosis","volume":"93","author":"Misumi","year":"2013","journal-title":"Lab. Investig."},{"key":"ref_139","doi-asserted-by":"crossref","unstructured":"Suenaga, G., Ikeda, T., Komohara, Y., Takamatsu, K., Kakuma, T., Tasaki, M., Misumi, Y., Ueda, M., Ito, T., and Senju, S. (2016). Involvement of macrophages in the pathogenesis of familial amyloid polyneuropathy and efficacy of human iPS cell-derived macrophages in its treatment. PLoS ONE, 11.","DOI":"10.1371\/journal.pone.0163944"},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"e19509","DOI":"10.1097\/MD.0000000000019509","article-title":"Fecal calprotectin levels are elevated in transthyretin amyloidosis patients with gastrointestinal manifestations","volume":"99","author":"Nakov","year":"2020","journal-title":"Medicine"},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1093\/eurheartj\/ehm066","article-title":"Vascular abnormalities in primary amyloidosis","volume":"28","author":"Modesto","year":"2007","journal-title":"Eur. Heart J."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1152\/ajpheart.00503.2011","article-title":"Human microvascular dysfunction and apoptotic injury induced by AL amyloidosis light chain proteins","volume":"301","author":"Migrino","year":"2011","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1007\/s40120-020-00210-7","article-title":"Transthyretin amyloidosis: Update on the clinical spectrum, pathogenesis, and disease-modifying therapies","volume":"9","author":"Koike","year":"2020","journal-title":"Neurol. Ther."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"9759735","DOI":"10.1155\/2017\/9759735","article-title":"Markers and biomarkers of endothelium; when something is rotten in the state","volume":"2017","author":"Goncharov","year":"2017","journal-title":"Oxid. Med. Cell. Longev."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1182\/blood-2016-02-702696","article-title":"Clinical and prognostic significance of serum levels of von Willebrand factor and ADAMSTS-13 antigens in AL amyloidosis","volume":"128","author":"Kastritis","year":"2016","journal-title":"Blood"},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s40120-016-0040-x","article-title":"Mechanism of Action and Clinical Application of Tafamidis in Hereditary Transthyretin Amyloidosis","volume":"5","author":"Coelho","year":"2016","journal-title":"Neurol. Ther."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/11\/9\/2360\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T22:59:09Z","timestamp":1760137149000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/11\/9\/2360"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,22]]},"references-count":146,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2022,5]]}},"alternative-id":["jcm11092360"],"URL":"https:\/\/doi.org\/10.3390\/jcm11092360","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,22]]}}}